Introduction
For many people living with advanced or metastatic hormone receptor-positive breast cancer, treatment often continues through multiple lines of endocrine therapy as the disease changes over time. Some cancers eventually develop genetic mutations that allow them to continue growing despite previous hormone-based treatments, making newer targeted therapies an important option.
Inluriyo is a prescription oral endocrine therapy approved for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy. As a selective estrogen receptor degrader (SERD), Inluriyo targets and breaks down estrogen receptors that help certain breast cancer cells grow. Because it specifically targets tumors with ESR1 mutations, treatment requires confirmation of the mutation using an FDA-approved companion diagnostic test.
As a specialty oncology medication, Inluriyo may carry significant treatment costs depending on insurance coverage and specialty pharmacy requirements. Many patients searching for the Inluriyo patient assistance program are looking for ways to reduce out-of-pocket expenses while maintaining access to therapy.
Prescription Hope offers qualified patients access to affordable medications through patient assistance programs.
What Is the Inluriyo Patient Assistance Program?
Understanding Inluriyo Prescription Assistance
Sadly, dealing with metastatic hormone receptor-positive breast cancer can mean massive financial burdens placed on a person going through treatment, as well as their loved ones.
Because of the cost of specialty medications like Inluriyo, pharmaceutical manufacturers often launch patient assistance programs to provide qualified patients with affordable brand-name medications.
However, many of these programs have been known to include complex application processes that leave patients feeling overwhelmed and frustrated.
Thankfully, there’s a solution.
How Expert Advocates Help Make Inluriyo More Affordable
Personalized Medication Assistance
When patients need prescription assistance specialists, Prescription Hope is there to help. Our team of patient advocates supports you throughout the patient assistance program application process. We manage form completion, document and signature collection, coordinating with healthcare providers and manufacturers, and more.
Ongoing Patient Support
Not only does Prescription Hope offer breast cancer medication support during the application process, but our team of patient access specialists continues to manage administrative tasks associated with ongoing patient assistance program enrollment.
They take care of things like document updates, yearly renewals, program monitoring, issue resolution, and even refill scheduling.
Inluriyo Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Navigating Breast Cancer Treatment Costs
Unfortunately, the SERD medication cost can be too much for most patients. Thankfully, Prescription Hope’s medication access service is a simple and consistent $70.00 per month, per medication.
All of our services are included with a low monthly rate. And, we never charge add-on fees, institute variable pricing, or charge medication costs.
Plus, if we can’t help you save, you don’t pay!
Inluriyo Patient Assistance Eligibility
General Eligibility Requirements
Many patients wonder, “who qualifies for Inluriyo assistance?” To learn the specific requirements, enroll with Prescription Hope.
All patient assistance programs set specific qualification standards; however, criteria typically fall under several general categories. Those include:
Income: All programs set their own income threshold standards.
Insurance: Every program differs on the status of insurance coverage that is acceptable for qualification.
Prescription: All qualified patients must have a valid prescription for the brand-name medication they wish to apply for.
U.S. Residency: All qualified patients must be legal U.S. residents.
Simple Enrollment With Expert Support
Getting Started With Enrollment
Patients who need prescription support services and are looking for patient assistance registration need look no further than Prescription Hope. Our enrollment process is only 6 simple steps:
- Submit Information: Prescription Hope’s online enrollment form only takes a few minutes to complete.
- Advocate Contact: Once we receive your enrollment form, a patient advocate will contact you within 1-2 business days.
- Document Collection: After prequalification, our team of patient advocates will collect your necessary documents.
- Provider Coordination: Plus, we coordinate with your healthcare provider to gather signatures.
- Program Submission: Once everything is in order, our team submits your application to the manufacturer for processing.
- Medication Delivery: After a patient is approved, they can typically expect to receive their medication within 2 weeks. All medication ships directly from the manufacturer to your home or doctor’s office.
Understanding Inluriyo
How Inluriyo Works
Inluriyo is a selective estrogen receptor degrader (SERD) that targets and breaks down estrogen receptors on many hormone receptor-positive breast cancer cells.
Some breast cancers depend on estrogen signaling to grow and spread. Inluriyo binds to the estrogen receptor, blocks its activity, and causes the receptor to degrade. Without functioning estrogen receptors, cancer cells receive fewer growth signals, helping slow or stop tumor growth.
Because Inluriyo specifically targets tumors with ESR1 mutations, patients must undergo biomarker testing using an FDA-approved companion diagnostic test before treatment begins.
What Conditions Does Inluriyo Treat?
Inluriyo is FDA-approved for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed following at least one line of endocrine therapy.
The medication is intended for patients whose breast cancer has spread beyond the breast or cannot be removed surgically and whose cancer continues to rely on estrogen signaling despite previous hormone-based treatment.
Because treatment is based on the presence of an ESR1 mutation, only patients whose tumors test positive using an FDA-approved companion diagnostic are eligible to receive Inluriyo.
Benefits of Treatment
Inluriyo provides a precision medicine approach for eligible patients with advanced hormone receptor-positive breast cancer by targeting and degrading estrogen receptors that help drive cancer growth.
Potential benefits include slowing disease progression, targeting ESR1-mutated tumors after prior endocrine therapy, delaying cancer progression, providing a convenient oral alternative to injectable endocrine therapies, offering personalized treatment based on a tumor’s genetic profile, and helping maintain quality of life by delaying disease progression.
Treatment outcomes vary among patients. Therapy generally continues as long as the medication remains effective and side effects are manageable, with routine monitoring by the oncology care team throughout treatment.
Important Safety Information and Side Effects
Inluriyo does not carry an FDA Boxed Warning.
The most commonly reported side effects include fatigue, hot flashes, muscle pain (myalgia), joint pain (arthralgia), nausea, diarrhea, constipation, decreased appetite, headache, and abdominal pain. Common laboratory abnormalities include increased liver enzyme levels (AST and ALT), increased cholesterol, increased triglycerides, decreased hemoglobin, decreased neutrophil count, decreased platelet count, and decreased calcium levels. Patients should contact their healthcare provider if side effects become severe or persistent.
Inluriyo may cause fetal harm if used during pregnancy. Females who can become pregnant should use effective contraception during treatment and for the recommended period after the last dose. Male patients with partners who can become pregnant should also follow contraceptive recommendations provided by their healthcare provider.
Patients with moderate or severe hepatic impairment may require dosage adjustment. Healthcare providers may evaluate liver function before treatment begins and monitor liver health during therapy.
Treatment may result in laboratory abnormalities, including increased liver enzymes, elevated cholesterol and triglycerides, decreased hemoglobin, decreased neutrophils, decreased platelets, and decreased calcium. Routine laboratory monitoring may be recommended throughout treatment.
Inluriyo interacts with medications that affect the CYP3A enzyme system. Strong CYP3A inhibitors and strong CYP3A inducers should generally be avoided when possible because they may affect how the medication works. If these medications cannot be avoided, dosage adjustments may be necessary. Patients should provide their healthcare provider with a complete list of prescription medications, over-the-counter medicines, vitamins, and herbal supplements before starting treatment.
Do not use Inluriyo during pregnancy because of the risk of fetal harm. Breastfeeding is not recommended during treatment and for the recommended period after the final dose. Patients who are pregnant, planning to become pregnant, or breastfeeding should discuss treatment options with their healthcare provider before beginning therapy.
Inluriyo is taken orally once daily as a tablet. It should be taken on an empty stomach, at least two hours before food or at least one hour after food, and at approximately the same time each day. Tablets should be swallowed whole. If a dose is missed or vomiting occurs after taking a dose, patients should follow the FDA-approved prescribing information or their healthcare provider’s instructions rather than taking an extra dose. Treatment generally continues until disease progression or unacceptable toxicity occurs.
Healthcare providers typically monitor liver function, complete blood counts, lipid levels, calcium levels, treatment response, and medication tolerability throughout therapy.
Access to Multiple Medications
Support Beyond Inluriyo
While getting breast cancer medication assistance is vital for Americans who struggle financially when it comes to their medication costs, many patients have more than one brand-name medication.
Prescription Hope offers access for qualified patients to multiple medication assistance programs. With a list of hundreds of available brand-name medications for access, Prescription Hope can help you with as many as you qualify for.
All for $70.00 per month, per medication.
Why Choose Prescription Hope for Inluriyo Assistance
Patient-Focused Medication Support
For 20 years, Prescription Hope has helped Americans get the prescription affordability support they need.
Our medication access specialists can help you get Inluriyo assistance through Prescription Hope for a low $70.00 per month, per medication.
Simplified Access to Specialty Medications
For metastatic breast cancer medication access, qualified patients pay $70.00 per month, per medication. That means no hassles, hidden fees, add-ons, or medication costs.
Ongoing Prescription Assistance
If you’re looking for long-term medication support, then Prescription Hope can help. We don’t just handle patient assistance program applications, but also manage the administrative tasks required for continued enrollment.
We handle document updates, yearly renewals, program monitoring, refill scheduling, and more.
If you need access to prescription affordability programs and are looking for ER-positive metastatic breast cancer treatment support, then be sure to enroll with Prescription Hope today to find out how we can help you ease the financial burden of your medication costs.